Literature DB >> 18668369

Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.

Stanley S Wallack1, Cindy Parks Thomas, Timothy C Martin, Jon Chilingerian, Sharon Reif.   

Abstract

Most substance abuse treatment occurs in outpatient treatment centers, necessitating an understanding of what motivates organizations to adopt new treatment modalities. Tichy's framework of organizations as being comprised of three intertwined internal systems (technical, cultural, and political) was used to explain treatment organizations' slow adoption of buprenorphine, a new medication for opiate dependence. Primary data were collected from substance abuse treatment organizations in four of the ten metropolitan areas with the largest number of heroin users. Only about one fifth offered buprenorphine. All three internal systems were important determinants of buprenorphine adoption in our multivariate model. However, the cultural system, measured by attitude toward medications, was a necessary condition for adoption. Health policies designed to encourage adoption of evidence-based performance measures typically focus on the technical system of organizations. These findings suggest that such policies would be more effective if they incorporate an understanding of all three internal systems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668369     DOI: 10.1007/s11414-008-9132-4

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  24 in total

Review 1.  Temporary firms in community hospitals: elements of a managerial theory of clinical efficiency.

Authors:  J A Chilingerian; M P Glavin
Journal:  Med Care Rev       Date:  1994

2.  Early experience with pay-for-performance: from concept to practice.

Authors:  Meredith B Rosenthal; Richard G Frank; Zhonghe Li; Arnold M Epstein
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

3.  Community based heroin addicts who turn to experimental treatment rather than conventional care.

Authors:  J Michaels; M Galanter; R Resnick; M Marmor; H Lifshutz; R Perrone
Journal:  J Addict Dis       Date:  1995

4.  Implementing evidence-based medicine: the role of market pressures, compensation incentives, and culture in physician organizations.

Authors:  S M Shortell; J L Zazzali; L R Burns; J A Alexander; R R Gillies; P P Budetti; T M Waters; H S Zuckerman
Journal:  Med Care       Date:  2001-07       Impact factor: 2.983

5.  Impact of relational coordination on quality of care, postoperative pain and functioning, and length of stay: a nine-hospital study of surgical patients.

Authors:  J H Gittell; K M Fairfield; B Bierbaum; W Head; R Jackson; M Kelly; R Laskin; S Lipson; J Siliski; T Thornhill; J Zuckerman
Journal:  Med Care       Date:  2000-08       Impact factor: 2.983

Review 6.  The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings.

Authors:  Kathryn E McCollister; Michael T French
Journal:  Addiction       Date:  2003-12       Impact factor: 6.526

7.  Adoption and implementation of new technologies in substance abuse treatment.

Authors:  Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2002-06

8.  A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

9.  Buprenorphine versus methadone maintenance for opioid dependence.

Authors:  T R Kosten; R Schottenfeld; D Ziedonis; J Falcioni
Journal:  J Nerv Ment Dis       Date:  1993-06       Impact factor: 2.254

10.  National trends in statin use by coronary heart disease risk category.

Authors:  Jun Ma; Niraj L Sehgal; John Z Ayanian; Randall S Stafford
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

View more
  20 in total

1.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

3.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

4.  The role of expectation in the therapeutic outcomes of alcohol and drug addiction treatments.

Authors:  Primavera A Spagnolo; Luana Colloca; Markus Heilig
Journal:  Alcohol Alcohol       Date:  2015-03-11       Impact factor: 2.826

5.  Financial factors and the implementation of medications for treating opioid use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

6.  Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Authors:  Christina M Andrews; Thomas A D'Aunno; Harold A Pollack; Peter D Friedmann
Journal:  Med Care Res Rev       Date:  2013-09-18       Impact factor: 3.929

7.  Preferences for evidence-based practice dissemination in addiction agencies serving women: a discrete-choice conjoint experiment.

Authors:  Charles E Cunningham; Joanna Henderson; Alison Niccols; Maureen Dobbins; Wendy Sword; Yvonne Chen; Stephanie Mielko; Karen Milligan; Ellen Lipman; Lehana Thabane; Louis Schmidt
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

Review 8.  Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Authors:  Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

9.  Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities.

Authors:  Traci Rieckmann; Anne E Kovas; Beth A Rutkowski
Journal:  J Psychoactive Drugs       Date:  2010-09

10.  Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.

Authors:  Helena B Hansen; Carole E Siegel; Brady G Case; David N Bertollo; Danae DiRocco; Marc Galanter
Journal:  J Behav Health Serv Res       Date:  2013-07       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.